logo
logo

Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics

Mar 02, 2021•over 4 years ago

Amount Raised

$13 Million

Seattle

Description

Presage Biosciences, Inc., a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology (CIVO®) intratumoral microdosing platform, today announced the closing of a $13 million financing and commencement of new research collaborations with Merck, known as MSD outside of the United States and Canada, and Maverick Therapeutics.

Company Information

Company

Civo And Phase 0 Trials

Location

Seattle, Washington, United States

About

Comparative In Vivo Oncology (CIVO) is Presage's patented platform that enables intratumoral microdosing and analysis of multiple cancer agents. Phase 0 trials, or Exploratory Investigational New Drug studies, allow for the evaluation of minute amounts of drugs in patients to assess pharmacodynamic effects. Presage is advancing the use of CIVO in Phase 0 trials in order to rapidly evaluate multiple drug candidates and enhance knowledge applicable for future trial design. A recently completed clinical trial demonstrated that CIVO is well tolerated and highlighted drug-specific tumor cell and microenvironment responses to both small molecule and biologic agents.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech